Trials / Completed
CompletedNCT01117480
Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA
Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA (REACH)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,013 (actual)
- Sponsor
- AbbVie (prior sponsor, Abbott) · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the clinical effectiveness and safety of adalimumab as used in routine clinical practice in adult participants with moderate to severe rheumatoid arthritis (RA) in Canada.
Detailed description
REACH is an observational survey of participants with moderate to severe rheumatoid arthritis taking adalimumab. Participants who volunteer will be asked to provide information about their medical history and experiences with adalimumab. No drug will be provided as a result of participation in the registry. All treatment decisions are independent of participation in the registry.
Conditions
Timeline
- Start date
- 2005-07-01
- Primary completion
- 2014-12-01
- Completion
- 2014-12-01
- First posted
- 2010-05-05
- Last updated
- 2016-02-24
- Results posted
- 2016-02-24
Source: ClinicalTrials.gov record NCT01117480. Inclusion in this directory is not an endorsement.